520 related articles for article (PubMed ID: 27631533)
1. Plate-based diversity subset screening generation 2: an improved paradigm for high-throughput screening of large compound files.
Bell AS; Bradley J; Everett JR; Loesel J; McLoughlin D; Mills J; Peakman MC; Sharp RE; Williams C; Zhu H
Mol Divers; 2016 Nov; 20(4):789-803. PubMed ID: 27631533
[TBL] [Abstract][Full Text] [Related]
2. Plate-based diversity subset screening: an efficient paradigm for high throughput screening of a large screening file.
Bell AS; Bradley J; Everett JR; Knight M; Loesel J; Mathias J; McLoughlin D; Mills J; Sharp RE; Williams C; Wood TP
Mol Divers; 2013 May; 17(2):319-35. PubMed ID: 23559278
[TBL] [Abstract][Full Text] [Related]
3. Novel trends in high-throughput screening.
Mayr LM; Bojanic D
Curr Opin Pharmacol; 2009 Oct; 9(5):580-8. PubMed ID: 19775937
[TBL] [Abstract][Full Text] [Related]
4. Biodiversity of small molecules--a new perspective in screening set selection.
Petrone PM; Wassermann AM; Lounkine E; Kutchukian P; Simms B; Jenkins J; Selzer P; Glick M
Drug Discov Today; 2013 Jul; 18(13-14):674-80. PubMed ID: 23454345
[TBL] [Abstract][Full Text] [Related]
5. Small-Molecule Library Subset Screening as an Aid for Accelerating Lead Identification.
Beresini MH; Liu Y; Dawes TD; Clark KR; Orren L; Schmidt S; Turincio R; Jones SW; Rodriguez RA; Thana P; Hascall D; Gross DP; Skelton NJ
J Biomol Screen; 2014 Jun; 19(5):758-70. PubMed ID: 24518067
[TBL] [Abstract][Full Text] [Related]
6. Plate-based diversity selection based on empirical HTS data to enhance the number of hits and their chemical diversity.
Sukuru SC; Jenkins JL; Beckwith RE; Scheiber J; Bender A; Mikhailov D; Davies JW; Glick M
J Biomol Screen; 2009 Jul; 14(6):690-9. PubMed ID: 19531667
[TBL] [Abstract][Full Text] [Related]
7. High-throughput screening normalized to biological response: application to antiviral drug discovery.
Patel DA; Patel AC; Nolan WC; Huang G; Romero AG; Charlton N; Agapov E; Zhang Y; Holtzman MJ
J Biomol Screen; 2014 Jan; 19(1):119-30. PubMed ID: 23860224
[TBL] [Abstract][Full Text] [Related]
8. Big pharma screening collections: more of the same or unique libraries? The AstraZeneca-Bayer Pharma AG case.
Kogej T; Blomberg N; Greasley PJ; Mundt S; Vainio MJ; Schamberger J; Schmidt G; Hüser J
Drug Discov Today; 2013 Oct; 18(19-20):1014-24. PubMed ID: 23127858
[TBL] [Abstract][Full Text] [Related]
9. Optimal HTS Fingerprint Definitions by Using a Desirability Function and a Genetic Algorithm.
Cortes Cabrera A; Petrone PM
J Chem Inf Model; 2018 Mar; 58(3):641-646. PubMed ID: 29425455
[TBL] [Abstract][Full Text] [Related]
10. Increasing the delivery of next generation therapeutics from high throughput screening libraries.
Wigglesworth MJ; Murray DC; Blackett CJ; Kossenjans M; Nissink JW
Curr Opin Chem Biol; 2015 Jun; 26():104-10. PubMed ID: 25909818
[TBL] [Abstract][Full Text] [Related]
11. The European Lead Factory: An updated HTS compound library for innovative drug discovery.
van Vlijmen H; Ortholand JY; Li VM; de Vlieger JSB
Drug Discov Today; 2021 Oct; 26(10):2406-2413. PubMed ID: 33892142
[TBL] [Abstract][Full Text] [Related]
12. Open access high throughput drug discovery in the public domain: a Mount Everest in the making.
Roy A; McDonald PR; Sittampalam S; Chaguturu R
Curr Pharm Biotechnol; 2010 Nov; 11(7):764-78. PubMed ID: 20809896
[TBL] [Abstract][Full Text] [Related]
13. Cheminformatics approaches to analyze diversity in compound screening libraries.
Akella LB; DeCaprio D
Curr Opin Chem Biol; 2010 Jun; 14(3):325-30. PubMed ID: 20457001
[TBL] [Abstract][Full Text] [Related]
14. How diverse are diversity assessment methods? A comparative analysis and benchmarking of molecular descriptor space.
Koutsoukas A; Paricharak S; Galloway WR; Spring DR; Ijzerman AP; Glen RC; Marcus D; Bender A
J Chem Inf Model; 2014 Jan; 54(1):230-42. PubMed ID: 24289493
[TBL] [Abstract][Full Text] [Related]
15. Stratified high-throughput screening sets enable flexible screening strategies from a single plated collection.
Nissink JW; Schmitt S; Blackburn S; Peters S
J Biomol Screen; 2014 Mar; 19(3):369-78. PubMed ID: 23918919
[TBL] [Abstract][Full Text] [Related]
16. Case studies of minimizing nonspecific inhibitors in HTS campaigns that use assay-ready plates.
Liu Y; Beresini MH; Johnson A; Mintzer R; Shah K; Clark K; Schmidt S; Lewis C; Liimatta M; Elliott LO; Gustafson A; Heise CE
J Biomol Screen; 2012 Feb; 17(2):225-36. PubMed ID: 21940710
[TBL] [Abstract][Full Text] [Related]
17. Just-in-Time Compound Pooling Increases Primary Screening Capacity without Compromising Screening Quality.
Elkin LL; Harden DG; Saldanha S; Ferguson H; Cheney DL; Pieniazek SN; Maloney DP; Zewinski J; O'Connell J; Banks M
J Biomol Screen; 2015 Jun; 20(5):577-87. PubMed ID: 25722344
[TBL] [Abstract][Full Text] [Related]
18. Shaping a screening file for maximal lead discovery efficiency and effectiveness: elimination of molecular redundancy.
Bakken GA; Bell AS; Boehm M; Everett JR; Gonzales R; Hepworth D; Klug-McLeod JL; Lanfear J; Loesel J; Mathias J; Wood TP
J Chem Inf Model; 2012 Nov; 52(11):2937-49. PubMed ID: 23062111
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Iterative Screening with Stepwise Compound Selection Based on Novartis In-house HTS Data.
Paricharak S; IJzerman AP; Bender A; Nigsch F
ACS Chem Biol; 2016 May; 11(5):1255-64. PubMed ID: 26878899
[TBL] [Abstract][Full Text] [Related]
20. Hit Discovery for Public Target Programs in the European Lead Factory: Experiences and Output from Assay Development and Ultra-High-Throughput Screening.
Honarnejad S; van Boeckel S; van den Hurk H; van Helden S
SLAS Discov; 2021 Feb; 26(2):192-204. PubMed ID: 32734803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
